Abstract. In recent years, the incidence of colorectal cancer (CRC) has increased and research into new treatment methods for CRC has become a hot topic. Naringin has an inhibitory effect on the PI3k/AKT/mTOR signaling pathway in various tumor cell types and the effect of naringin is closely related to the occurrence and proliferation of tumor cells. The aim of this present study was to investigate whether naringin could inhibit the proliferation of CRC cells by inhibiting the PI3K/AKT/mTOR signaling pathway. This could provide a more mechanism-based treatment for CRC. MTT assays were used to detect the proliferation of CRC cells treated with various concentrations of naringin. The degree of apoptosis and the expression of apoptosis-related proteins (Bcl-2 and Bax) in CRC cells stimulated by naringin was detected using flow cytometry and western blot assays, respectively. The expression levels of PI3K/AKT/mTOR-related proteins [PI3K, AKT, mTOR, phosphorylated (p)-PI3K, p-AKT and p-mTOR] after naringin stimulation in CRC cells were detected using western blot assays. Naringin inhibited the proliferation of CRC cells in a dose-dependent manner. Naringin promoted the apoptosis of CRC cells and inhibited the activation of the PI3K/AKT/mTOR signaling pathway in a dose-dependent manner. The results demonstrated that naringin may be a promising therapeutic agent for the treatment of CRC, which may inhibit the proliferation of CRC cells and induce apoptosis by inhibiting the PI3K/AKT/mTOR signaling pathway.

Introduction

Colorectal cancer (CRC) is one of the most common malignant tumor types and the second most common cancer in females worldwide in 2012 (1). In recent years, due to environmental and dietary effects, the number of patients suffering from CRC has increased annually (2). Currently, the primary methods for treating CRC are surgery, radiotherapy and chemotherapy (3,4). Furthermore, following surgery, patients often have reduced gastrointestinal function, reduced immunity and also require cumbersome nursing care (5). As a result, the pain caused by subsequent radiotherapy and chemotherapy also increases (6). Therefore, targeted drugs play an important role in the treatment of CRC (7-11). Commonly used targeted drugs for the treatment of CRC are those targeting the epidermal growth factor receptor and targeting vascular endothelial growth factor (VEGF) (12). However, due to problems arising from drug resistance (13), it is important to investigate further effective compounds targeting alternative signaling pathways.

Frydoonfar et al (14) found that naringenin had a significant inhibitory effect on colon cancer cell proliferation and that 0.71 mM naringenin significantly inhibited colon cell proliferation. This highlighted naringenin as a promising compound for further investigation. Naringin is a dihydroflavonoid with a variety of biological activities such as anti-oxidation, anti-inflammatory, anti-mutation and analgesic activities (15). Furthermore, previous studies have found that naringin inhibits the proliferation of breast cancer and cervical cancer cells (16-19). In addition, naringin can inhibit the biological function of tumors by inhibiting the excessive activation of the PI3K/AKT/mTOR signaling pathway (20). In recent years, the PI3K/AKT/mTOR signaling pathway has been identified as a key target of tumor-targeted therapy (21-24). The PI3K/AKT/mTOR signaling pathway is important to regulate the proliferation, growth, migration and survival of tumor cells (25,26). It has been reported that the occurrence of CRC is linked to the PI3K/AKT/mTOR signaling pathway (27,28). Moreover, 60-70% of colon cancer patients present AKT signaling activation and a reduction in PTEN expression levels (28). A previous study has found that the expression levels of phosphorylated (p)-AKT are higher in CRC lesions or metastatic lesions and the probability of raised mTOR

Correspondence to: Dr Liyue Ge or Dr Guangyi Gao, Department of Traditional Chinese Medicine, Huaian Second People's Hospital, The Affiliated Huaian Hospital of Xuzhou Medical University, 62 Huaihai South Road, Huaian, Jiangsu 223001, P.R. China
E-mail: geliyue2602@163.com
E-mail: gaogy190626@163.com

*Contributed equally

Key words: colorectal cancer, naringin, PI3K/AKT/mTOR pathway
expression levels was also increased following PI3K mutations
and the loss of PTEN expression (27).

Based on these findings, this present study aimed to inves-
tigate whether naringin could inhibit the proliferation of CRC
cells by inhibiting the PI3K/AKT/mTOR signaling pathway, so
as to potentially provide a more mechanisms-based treatment
for CRC.

Materials and methods

Materials. Naringin was purchased from Beijing Solarbio
Science & Technology Co., Ltd. Human HCT116 and SW620
CRC cell lines were purchased from The Cell Bank of Type
Culture Collection of the Chinese Academy of Sciences.

Cell culture. HCT116 cells were maintained in McCoy's 5A
medium (Gibco; Thermo Fisher Scientific, Inc.) and SW620
cells were maintained in L-15 medium (Gibco; Thermo Fisher
Scientific, Inc.). Both media were supplemented with 10% FBS
(Gibco; Thermo Fisher Scientific, Inc.) and the cells were
cultured at 37°C in a 5% CO2 incubator.

MTT assay. Cells (5x104 cells/well) were seeded into 96-well
plates and cultured for 24 h, then supplemented with fresh
medium for naringin treatment. After the cells were incubated
with naringin (0, 6, 12 or 25 µg/ml) (29) for 24, 48 and 72 h, the
medium was removed and 30 µl MTT (0.5 mg/ml) was added
to each well, prior to further incubation for 4 h. Subsequently,
100 µl DMSO (Sigma-Aldrich; Thermo Fisher Scientific, Inc.)
was added to each well. The optical density values were then
measured at 490 nm using a micro-plate reader (BioTek China).

Measurement of cell apoptosis using flow cytometry. After
incubation with naringin (0, 6, 12 or 25 µg/ml) for 48 h in
6-well plates (5x104 cells/well), the cells were collected using
trypsin digestion without EDTA and then centrifugated at room
temperature at 1,000 x g for 5 min. Subsequently, the cells
were re-suspended in 300 µl of 1X binding buffer (Beyotime
Institute of Biotechnology). A total of 5 µl of Annexin V-FITC
(Beyotime Institute of Biotechnology) was added to the samples
and mixed for 15 min at room temperature in the dark. Subsequently, 5 µl of propidium iodide (Beyotime Institute of Biotechnology) was added for 5 min. The samples
were analyzed using a flow cytometer (FACSCalibur; BD Biosciences). FlowJo software (version 7.6.1; FlowJo LLC) was used to analyze the data.

Western blot assay. Cells in six-well plates (5x104 cells/well)
were stimulated with naringin (0, 6, 12 or 25 µg/ml) for 48 h and
then washed with PBS. After the above procedure, the cellular
proteins were harvested and lysed using RIPA buffer (Beyotime
Institute of Biotechnology) at 4°C for 30 min. A bicinecinonic
acid protein assay kit (Pierce; Thermo Fisher Scientific, Inc.)
was used to measure protein concentration. Samples (40 µg/lane) were separated on 12% SDS-polyacrylamide gels and transblotted onto a PVDF membrane by electroblotting.
The PVDF membrane was blocked with 5% skim milk for 2 h
at room temperature. Subsequently, the membrane was incu-
bated overnight with the following primary antibodies: Bcl-2
(1:1,000; cat. no. 4223; Cell Signaling Technology, Inc.), Bax
(1:1,000; cat. no. 5023; Cell Signaling Technology, Inc.), PI3K
(1:1,000; cat. no. 4257; Cell Signaling Technology, Inc.), phos-
phorylated (p)-PI3K (1:1,000; cat. no. 17366; Cell Signaling
Technology, Inc.), AKT (1:1,000; cat. no. 9272; Cell Signaling
Technology, Inc.), p-AKT (1:1,000; cat. no. 4060; Cell
Signaling Technology, Inc.), mTOR (1:1,000; cat. no. 2972;
Cell Signaling Technology, Inc.), p-mTOR (1:1,000; cat. no.
5536; Cell Signaling Technology, Inc.) and GAPDH (1:1,000;
cat. no. 5174; Cell Signaling Technology, Inc.) at 4°C,
followed by incubation with horseradish peroxidase-conju-
gated anti-rabbit secondary antibody (1:2,000; cat. no. 7074;
Cell Signaling Technology, Inc.) for 1 h at room temperature.
The immunoreactive bands were visualized using an ECL
detection kit (Thermo Fisher Scientific, Inc.). GAPDH signal
was used to normalize protein loading. Band densities were
quantified using Gel-Pro Analyzer densitometry software
(version 6.3; Media Cybernetics, Inc.).

Statistical analysis. Data analyses were performed using
SPSS 18.0 statistical software (SPSS, Inc.). The data are
expressed as the mean ± SD of ≥3 separate experiments
and the differences between groups were determined using
unpaired Student's t-tests or one-way ANOVAs with Tukey's
post hoc tests. P<0.05 was considered to indicate a statistically
significant difference.

Results

Naringin effectively inhibits the proliferation of CRC cells.
The structural formula of naringin is shown in Fig. 1. To
investigate the function of naringin in CRC, MTT assays
were used to detect cell proliferation. The results showed that
naringin had a significant inhibitory effect on the prolifera-
tion of CRC (SW620 and HCT116 cells) cells and showed a
concentration-dependent effect (Fig. 2).

Naringin promotes apoptosis in CRC cells. It was demon-
strated that naringin had an effect on apoptosis in CRC
cells. The results of the apoptosis assay showed that naringin
promoted the apoptosis of SW620 (Fig. 3A and B) and
HCT116 cells (Fig. 3C and D). There also appeared to be a
positive association between the concentration of naringin
and the extent of apoptosis. Combined with the results of the
western blot assays, this conclusion was further verified. The
results of the western blot assays demonstrated that naringin
effectively reduced the expression levels of Bcl-2, an inhibitor
Figure 2. Effect of naringin on colorectal cancer cell proliferation. (A) SW620 and (B) HCT116 cells were treated with different concentrations (6, 12 or 25 µg/ml) of naringin for 12, 24 or 48 h at 37˚C. Cell proliferation was determined using MTT assays. Data are expressed as the mean ± SD. *P<0.05 and **P<0.01 vs. 0 µg/ml naringin treatment group. OD, optical density.

Figure 3. Effect of naringin on colorectal cancer cell apoptosis. (A) Representative flow cytometry graphs of SW620 cells treated with different concentrations (6, 12 or 25 µg/ml) of naringin for 48 h at 37˚C and (B) the apoptosis rate was calculated following treatment. (C) Representative flow cytometry graphs of HCT116 cells treated with different concentrations (6, 12 or 25 µg/ml) of naringin for 48 h at 37˚C and (D) the apoptosis rate was calculated following treatment. Data are presented as the mean ± SD. *P<0.05 and **P<0.01 vs. 0 µg/ml naringin treatment group. PI, propidium iodide.
of apoptosis. Naringin also increased the expression levels of Bax, a pro-apoptotic protein, in SW620 (Fig. 4A) and HCT116 cells (Fig. 4B).

**Naringin effectively inhibits the PI3K/AKT/mTOR signaling pathway.** The specific effects of naringin on the PI3K/AKT/mTOR signaling pathway were investigated in CRC cells. After SW620 and HCT116 cells were treated with serial concentrations of naringin for 48 h, the expression levels of PI3K, phosphorylated (p)-PI3K, AKT, p-AKT, mTOR and p-mTOR were detected using western blot assays. The results showed that there was no significant change in the expression levels of PI3K, AKT and mTOR. However, the expression levels of p-PI3K, p-AKT and p-mTOR were significantly down-regulated with increasing naringin concentrations in SW620 (Fig. 5A, D and G) and HCT116 cells (Fig. 6A, D and G). After calculating the ratios of p-PI3K/PI3K, p-AKT/AKT and p-mTOR/mTOR, it was found that the ratios of these
three phosphorylated proteins in SW620 (Fig. 5B, E and H) and HCT116 (Fig. 6B, E and H) cells were downregulated with increasing naringin concentrations. No significant differences were observed in the mRNA expression levels of PI3K, AKT and mTOR in both SW620 (Fig. 5C, F and I) and HCT116 (Fig. 6C, F and I) cells. These results indicated that naringin has a dose-dependent inhibitory effect on the PI3K/AKT/mTOR signaling pathway in CRC cells.

Discussion

CRC has demonstrated an increasing incidence in recent years (2). For patients with CRC, postoperative ostomy care is difficult and gastrointestinal function is impaired, resulting in a lower quality of life and increasing the extent of pain during subsequent radiotherapy and chemotherapy (5,6). Therefore, investigating new therapeutic methods for treating CRC, new effective compounds and novel signaling pathways have become areas of focus for research in recent years.

Naringin was the compound of focus in the present study. MTT assays were used to detect the proliferation rate of CRC cells treated with naringin. Naringin was found to effectively inhibit CRC cell proliferation in both HCT116 and SW620 cells. Similarly, naringin demonstrated both time- and dose-dependent significant effects on proliferation. Combined with flow cytometry results examining the rate of apoptosis in CRC cells, it was found that naringin had a dose-dependent effect on the apoptosis of CRC cells, with higher doses causing an increase in the extent of apoptosis.

The role of naringin in CRC requires investigation at the molecular level. The PI3K/AKT/mTOR signaling pathway is an important pathway for inhibiting cellular functions (28,30,31). In addition, there are numerous factors that are involved with the PI3K/AKT/mTOR signaling pathway, such as VEGF (32), PTEN (26,30), Bax and Bcl-2 (31). Furthermore, Pandurangan (28) demonstrated that the PI3K/AKT/mTOR signaling pathway is also a potentially effective target for treating CRC. Therefore, western blotting was used to...
investigate the expression levels of Bax, Bcl-2, PI3K, AKT and mTOR.

The western blotting results showed that naringin effectively promoted the expression of Bax, but inhibited the expression of Bcl-2 in a concentration-dependent manner. Elevated expression of Bax is usually associated with apoptosis, while decreased expression levels of Bcl-2 demonstrate a reduced ability to inhibit apoptosis (33). Bax is a pro-apoptotic member of the Bcl-2 family and it is closely related to PI3K pathway (33,34). Molton et al (35) found that CC139 fibroblasts treated with PI3K inhibitors showed a downregulation of Bcl-2. Furthermore, the study showed that the ability of Bax to activate and induce apoptosis was inhibited by the PI3K/AKT/mTOR signaling pathway (35). According to these results, it can be deduced that the PI3K pathway was suppressed by naringin.

To verify the above inference, western blotting was used to detect changes in the expression levels of PI3K, p-PI3K, AKT, p-AKT, mTOR and p-mTOR. The results showed no significant changes in the expression levels of PI3K, AKT or mTOR, but the expression levels of p-PI3K, p-AKT and p-mTOR showed a dose-dependent decrease when CRC cells were treated with naringin. Similarly, the ratio of p-PI3K/Pi3K, p-AKT/AKT and p-mTOR/mTOR also showed a dose-dependent downregulation. A decrease in the expression levels of p-PI3K, p-AKT and p-mTOR demonstrate reduced phosphorylation of PI3K, AKT and mTOR, further indicating that the PI3K/AKT/mTOR signaling pathway had been inhibited. These data also provided strong evidence that naringin may effectively inhibit the proliferation and promote the apoptosis of CRC cells.

Colakoglu et al (27) also observed that the loss of PTEN expression was closely related to the occurrence of CRC. Loss of PTEN expression leads to the activation of AKT and PI3K, which in turn promotes β-catenin phosphorylation and the malignant proliferation of cancer cells, which is common in cases of CRC (36-38). However, naringin can inhibit this reaction to some extent (39).

In conclusion, the prevention and treatment of CRC through the PI3K/AKT/mTOR signaling pathway is a feasible direction for future research. naringin inhibited the proliferation of CRC cells and induced apoptosis by inhibiting the PI3K/AKT/mTOR signaling pathway. Therefore, naringin may be a potential therapeutic agent for the treatment of CRC, which can inhibit the proliferation of CRC cells and induce apoptosis by inhibiting the PI3K/AKT/mTOR signaling pathway.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

HC, XJ and QZ contributed to study design, data collection, statistical analysis, data interpretation and manuscript preparation. JM, RC, HY, HS, and XZ contributed to data collection and statistical analysis. LG and GG contributed to data collection, statistical analysis and manuscript preparation. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin 65: 87-108, 2015.
2. Gupta N, Kupfer SS and Davis AM: Colorectal Cancer Screening. JAMA 321: 2022-2023, 2019.
3. Kuipers EJ, Grady WM, Lieberman D, Seuflerlein T, Sung JI, Boelens PG, van de Velde CJ and Watanabe T: Colorectal cancer. Nat Rev Dis Primers 1: 15065, 2015.
4. Al-Hajeri M, Marshall JL and Smaglo BG: Neoadjuvant Treatment for Surgically Resectable Metastatic Colorectal Cancer. Oncology (Williston Park) 30: 10-16, 2016.
5. Wang TY, Meng JH and Mai SC: Electrocupuncture Treatment Conduced Before and After Surgery Is Better in Promoting Reco-very of Gastrointestinal Function in Colorectal Cancer Patients Undergoing Radical Resection. Zhen Ci Yan Jiu 43: 797-800, 2018 (in Chinese).
6. Drury A, Payne S and Brady AM: The cost of survival: An exploration of colorectal cancer survivors’ experiences of pain. Acta Oncol 56: 205-211, 2017.
7. Wang D, Chen J, Chen H, Duan Z, Xu Q, Wei M, Wang L and Zhong M: Leptin regulates proliferation and apoptosis of colorectal carcinoma through PI3K/Akt/mTOR signalling pathway. J Biosci 37: 91-101, 2012.
8. Kocic B, Kitic D and Brankovic S: Dietary flavonoid intake and colorectal cancer risk: Evidence from human population studies. J BUON 18: 34-43, 2013.
9. Jonker DJ, O’Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahm M, Price T, Simes RJ, et al: Cetuximab for the treatment of colorectal cancer. N Engl J Med 357: 2040-2048, 2007.
10. Van Cutsem E, Köhne CH, Hitre E, Zaluzi J, Chang Chien CR, Makhson A, D’Haens G, Pintér T, Lim R, Bodoky G, et al: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360: 1408-1417, 2009.
11. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342, 2004.
12. Dienstmann R, De Dosso S, Felip E and Tabernero J: Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer. Mol Oncol 6: 15-26, 2012.
13. Van der Jeught K, Xu HC, Li YJ, Lu XB and Ji G: Drug resistance development to overcome resistance to EGFR inhibitors in lung and colorectal cancer. Mol Oncol 56: 205-211, 2017.
14. Frydoonfar HR, McGrath DR and Spigelman AD: The variable effect on proliferation of a colon cancer cell line by the citrus fruit flavonoid Naringenin. Colorectal Dis 5: 149-152, 2003.
15. Chen R, Qi QL, Wang MT and Li QY: Therapeutic potential of naringin: An overview. Pharm Biol 54: 3203-3210, 2016.
16. Yoshinaga A, Kajiva N, Oishi K, Kamada Y, Ikeda A, Chigwechokha PK, Kibe T, Kishida M, Kishida S, Komatsu M, et al.: NEU3 inhibitory effect of naringin suppresses cancer cell growth by attenuation of EGFR signaling through GM3 ganglioside accumulation. Eur J Pharmacol 782: 21-29, 2016.

17. Li H, Yang B, Huang J, Xiang T, Yin X, Wan J, Luo F, Zhang L, Li H and Ren G: Naringin inhibits growth potential of human triple-negative breast cancer cells by targeting β-catenin signaling pathway. Toxicol Lett 220: 219-228, 2013.

18. Zeng L, Zhen Y, Chen Y, Zou L, Zhang Y, Hu F, Feng J, Shen J and Wei B: Naringin inhibits growth and induces apoptosis by a mechanism dependent on reduced activation of NF-κB/COX-2-caspase-1 pathway in HeLa cervical cancer cells. Int J Oncol 45: 1929-1936, 2014.

19. Ramesh E and Alshatwi AA: Naringin induces death receptor and mitochondria-mediated apoptosis in human cervical cancer (SiHa) cells. Food Chem Toxicol 51: 97-105, 2013.

20. Raha S, Yunnam S, Hong GE, Lee HJ, Saralamma VV, Park HS, Heo JD, Lee SJ, Kim EH, Kim JA, et al.: Naringin induces autophagy-mediated growth inhibition by downregulating the PI3K/Akt/mTOR cascade via activation of MAPK pathways in AGS cancer cells. Int J Oncol 47: 1061-1069, 2015.

21. Morgenztern D and McLeod HL: PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 16: 797-803, 2005.

22. Scartozzi M, Giampieri R, Maccaroni E, Mandolesi A, Biagetti S, Alfonso S, Giustini L, Lorettelli C, Faloppi L, Bittoni A, et al.: Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab. J Transl Med 10: 71, 2012.

23. Oikonomou E and Pintzas A: Cancer genetics of sporadic colorectal cancer: BRAF and PI3KCA mutations, their impact on signaling and novel targeted therapies. Anticancer Res 26A: 1077-1084, 2006.

24. Francipane MG and Lagasse E: mTOR pathway in colorectal cancer: An update. Oncotarget 5: 2119-2126, 2020.

25. Molton SA, Todd DE and Cook SJ: Selective activation of the c-Jun N-terminal kinase (JNK) pathway fails to elicit Bax activation or apoptosis unless the phosphoinositide 3' -kinase (PI3K) pathway is inhibited. Oncogene 22: 4690-4701, 2003.

26. Ma J, Sawai H, Ochto N, Matsuyo T, Xu D, Yasuda A, Takahashi H, Wakisugi T and Takeyama H: PTEN regulates angiogenesis and VEGF expression of Bcl-2/Bax and caspase-3 in cerebral infarction rats through PTEN/PI3K/Akt signaling pathway. Exp Ther Med 19: 2119-2126, 2020.

27. Wang Y, Gu J, Hu L, Kong L, Wang T, Di M, Li C and Gui S: miR-130a alleviates neuronal apoptosis and changes in expression of Bcl-2/Bax and caspase-3 in cerebral infarction rats through PTEN/PI3K/Akt signaling pathway. Exp Ther Med 19: 2119-2126, 2020.

28. Purandaran AK: Potential targets for prevention of colorectal cancer: A focus on PI3K/Akt/mTOR and Wnt pathways. Asian Pac J Cancer Prev 14: 2201-2205, 2013.